← Search

Table · dataset · 2026

Solid modification strategies for active pharmaceutical ingredients (APIs): a systematic review on approaches, improvements, and limitations

Listed in figshare

<p>Poor aqueous solubility remains a major barrier in drug development, affecting approximately 40% of marketed drugs, up to 75% of drugs under development, and nearly 90% of new chemical entities.

Description

To overcome this limitation, solid modification of active pharmaceutical ingredients (APIs) emerged as a strategy to enhance drug physicochemical properties, particularly for Biopharmaceutics Classification System (BCS) II and IV drugs.

This review systematically analyzes recent advancements in solid modification techniques, including salt formation, cocrystallization, polymorphs, solvate and hydrate forms, amorphous and co-amorphous systems, inclusion complexes, and nanocrystallization. A systematic literature search spanning 2020–2025 was conducted using PubMed and ScienceDirect databases, focusing on studies that improve the physicochemical properties of the APIs.

Read the rest (2 more)

By categorizing APIs, matrices, and methods of each study, this review shows the most frequently used techniques and their matrices, advantages, and limitations of each modification, providing insights for optimizing drug performance and future research in pharmaceutical development. Among the various approaches reviewed, cocrystals, amorphous systems, nanocrystals, and inclusion complexes emerged as the most frequently used techniques.

Amorphous systems and inclusion complexes offer the highest median solubility enhancements by maximizing kinetic supersaturation or equilibrium solubility, respectively, while nanocrystals efficiently improve equilibrium solubility <i>via</i> particle size reduction, and cocrystals provide reliable, moderate gains with superior long-term thermodynamic stability.</p>

Links

Where it is published

Catalogue records · 1

Topics

Provenance · 1 source records, 18 field assertions
SourceKeyLast seenRaw
figshareoai:figshare.com:article/3394095411 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · figshare comconnector:figshare_com@1.0.0
concepts[field].anzsrc:field:320211mapping · figshare comvocabulary-mapper@1.0.0keywords['Infectious Diseases']
concepts[field].anzsrc:field:440710mapping · figshare comvocabulary-mapper@1.0.0keywords['Science Policy']
concepts[field].local:field:astronomymapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:chemistrymapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:computer-science-aimapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:earth-environmentalmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:economics-financemapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:engineeringmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:humanitiesmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:life-sciencesmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:medicine-healthmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:ocean-atmosphericmapping · figshare comconnector:figshare_com@1.0.0
concepts[field].local:field:social-sciencemapping · figshare comconnector:figshare_com@1.0.0
descriptionsource · figshare comconnector:figshare_com@1.0.0/metadata/dc/description
licensesource · figshare comconnector:figshare_com@1.0.0/metadata/dc/rights
publication_datesource · figshare comconnector:figshare_com@1.0.0
titlesource · figshare comconnector:figshare_com@1.0.0/metadata/dc/title